Page 2346 - Williams Hematology ( PDFDrive )

2320 Part XII: Hemostasis and Thrombosis Chapter 135: Fibrinolysis and Thrombolysis 2321

77. Mandle RJ, Kaplan AP: Hageman factor-dependent fibrinolysis: Generation of fibrino- 112. Van Hinsbergh VW, Bauer KA, Kooistra T, et al: Progress of fibrinolysis during tumor
lytic activity by the interaction of human activated factor XI and plasminogen. Blood necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen
54:850–862, 1979. activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation prod-
78. Goldsmith GH, Saito H, Ratnoff OD: The activation of plasminogen by Hageman factor ucts. Blood 76:2284–2289, 1990.
(factor XII) and Hageman factor fragments. J Clin Invest 62:54–60, 1978. 113. Schleef RR, Bevilacqua MP, Sawdey M, et al: Cytokine activation of vascular endothe-
79. Ouimet H, Loscalzo J, Schafer AI: Fibrinolysis, in Thrombosis and Hemorrhage, vol 1, lium: Effects on tissue-type plasminogen activator and type 1 plasminogen activator
edited by J Loscalzo and AI Schafer, p 127. Blackwell Scientific, Boston, 1994. inhibitor. J Biol Chem 263:5797–5803, 1988.
80. Hiraoka N, Allen E, Apel IJ, et al: Matrix metalloproteinases regulate neovasculariza- 114. Craik CS, Rutter WJ, Fletternick R: Splice junctions: Association with variation in pro-
tion by acting as pericellular fibrinolysins. Cell 95:365–377, 1998. tein structure. Science 220:1125–1129, 1983.
81. Hrafnkelsdottir T, Ottosson P, Gudnason T, et al: Impaired endothelial release of tissue- 115. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J: Secretion of plasminogen activator
type plasminogen activator in patients with chronic kidney disease and hypertension. inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low
Hypertension 44:300–304, 2004. density lipoprotein. Arteriosclerosis 10:1067–1073, 1990.
82. Patrassi GM, Sartori MT, Viero ML, et al: Venous thrombosis and tissue plasminogen 116. Etingin OR, Hajjar DP, Hajjar KA, et al: Lipoprotein(a) regulates plasminogen activator
activator release deficiency: A family study. Blood Coagul Fibrinolysis 2:231–235, 1991. inhibitor-1 expression in endothelial cells. J Biol Chem 266:2459–2465, 1990.
83. Sjogren LS, Doroudi R, Gan L, et al: Elevated intraluminal pressure inhibits vascu- 117. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasmino-
lar tissue plasminogen activator secretion and downregulates its gene expression. gen activator inhibitor-1 in cultured endothelial cells. A potential link between the ren-
Hypertension 35:1002–1008, 2000. in-angiotensin system and thrombosis. J Clin Invest 95:995–1001, 1995.
84. Carmeliet P, Schoonjans L, Kieckens L, et al: Physiological consequences of loss of plas- 118. Gelehrter TD, Scyncer-Laszuk R. Thrombin induction of plasminogen activator-
minogen activator gene function in mice. Nature 368:419–424, 1994. inhibitor synthesis in vitro. J Clin Invest 77:165–169, 1986.
85. Rau JC, Beaulieu LM, Huntington JA, Church FC: Serpins in thrombosis, hemostasis 119. Van Hinsbergh VW, Sprengers ED, Kooistra T: Effect of thrombin on the production of
and fibrinolysis. J Thromb Haemost 5:102–115, 2007. plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothe-
86. Aoki N: The past, present and future of plasmin inhibitor. Thromb Res 116:455–464, lial cells. Thromb Haemost 57:148–153, 1987.
2005. 120. Scarpati EM, Sadler JE: Regulation of endothelial cell coagulant properties. Modula-
87. Holmes WE, Nelles L, Lijnen HR: Primary structure of human alpha2-antiplasmin, a tion of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol
serine protease inhibitor (serpin). J Biol Chem 262:1659–1664, 1987. 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 264:20705–20713, 1989.
88. Hirosawa S, Nakamura Y, Miura O, et al: Organization of the human alpha2-antiplas- 121. Konkle BA, Kollros PR, Kelly MD: Heparin-binding growth factor-1 modulation of
min inhibitor gene. Proc Natl Acad Sci U S A 85:6836–6840, 1988. plasminogen activator inhibitor-1 expression. J Biol Chem 265:21867–21873, 1990.
89. Plow EF, Collen D: The presence and release of alpha-2-antiplasmin from human plate- 122. Erickson LA, Fici GJ, Lund JE, et al: Development of venous occlusions in transgenic
lets. Blood 58:1069–1074, 1981. mice for the plasminogen activator inhibitor-1 gene. Nature 346:74–76, 1990.
90. Lijnen HR, Okada K, Matsuo O, et al: Alpha2-Antiplasmin gene deficiency in mice is 123. Carmeliet P, Kieckens L, Schoonjans L, et al: Plasminogen activator inhibitor-1
associated with enhanced fibrinolytic potential without overt bleeding. Blood 93:2274– gene-deficient mice: I. Generation by homologous recombination and characterization.
2281, 1999. J Clin Invest 92:2746–2755, 1993.
91. Aoki N, Moroi M, Tachiya K: Effects of alpha-2-plasmin inhibitor on fibrin clot lysis. Its 124. Carmeliet P, Stassen JM, Schoonjans L, et al: Plasminogen activator inhibitor-1 gene-
comparison with alpha-2-macroglobulin. Thromb Haemost 39:22–31, 1978. deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest
92. Huisman LG, Van Griensven JM, Kluft C: On the role of C1-inhibitor as inhibitor of 92:2756–2760, 1993.
tissue-type plasminogen activator in human plasma. Thromb Haemost 73:466–471, 1995. 125. Fay WP, Shapiro AD, Shih JL, et al: Complete deficiency of plasminogen activator
93. Scott RW, Bergman BL, Bajpai A, et al: Protease nexin: Properties and a modified puri- inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327:1729–1733, 1992.
fication procedure. J Biol Chem 260:7029–7034, 1985. 126. Ye RD, Wun TC, Sadler JE: CDNA cloning and expression in Escherichia coli of a plas-
94. Cunningham DD, Van Nostrand WE, Farrell DH, Campbell CH: Interactions of serine minogen activator inhibitor from human placenta. J Biol Chem 262:3718–3725, 1987.
proteases with cultured fibroblasts. J Cell Biochem 32:281–291, 1986. 127. Ye RD, Aherns SM, Le Beau MM, et al: Structure of the gene for human plasminogen
95. Sprengers ED, Kluft D: Plasminogen activator inhibitors. Blood 69:381–387, 1987. activator inhibitor-2. The nearest mammalian homologue of chicken ovalbumin. J Biol
96. Ny T, Sawdey M, Lawrence D, et al: Cloning and sequence of a cDNA coding for the Chem 264:5495–5502, 1989.
human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl 128. Ogbourne SM, Antalis TM: Characterization of PAUSE-1, a powerful silencer in
Acad Sci U S A 83:6776–6780, 1986. the human plasminogen activator inhibitor type 2 gene promoter. Nucleic Acids Res
97. Kruithof EK: Plasminogen activator inhibitor type 1: Biochemical, biological, and clin- 29:3919–3927, 2001.
ical aspects. Fibrinolysis 2:59–70, 1988. 129. Antalis TM, Clok MA, Barnes T, et al: Cloning and expression of a cDNA coding for
98. Samad F, Yamamoto K, Loskutoff DJ: Distribution and regulation of plasminogen acti- a human monocyte-derived plasminogen activator inhibitor. Proc Natl Acad Sci U S A
vator inhibitor-1 in murine adipose tissue in vivo. J Clin Invest 97:37–46, 1996. 85:985–989, 1988.
99. Sawdey M, Podor TJ, Loskutoff DJ: Regulation of type-1 plasminogen activator inhibi- 130. Schleuning WD, Medcalf RL, Hession C, et al: Plasminogen activator inhibitor 2: Reg-
tor gene expression in cultured bovine aortic endothelial cells. J Biol Chem 264:10396– ulation of gene transcription during phorbol ester-mediated differentiation of U-937
10401, 1989. human histiocytic lymphoma cells. Mol Cell Biol 7:4564–4567, 1987.
100. Van den Berg EA, Sprengers ED, Jaye M, et al: Regulation of plasminogen activator 131. Chapman HA, Stone OL: A fibrinolytic inhibitor of human alveolar macrophages.
inhibitor-1 mRNA in human endothelial cells. Thromb Haemost 60:63–67, 1988. Induction with endotoxin. Am Rev Respir Dis 132:569–575, 1985.
101. Van Hinsbergh VW, Van den Berg EA, Fiers W, Dooijewaard G: Tumor necrosis factor 132. Nesheim M, Wang W, Boffa M, et al: Thrombin, thrombomodulin and TAFI in the
induces the production of urokinase-type plasminogen activator by human endothelial molecular link between coagulation and fibrinolysis. Thromb Haemost 78:386–391,
cells. Blood 75:1991–1998, 1990. 1997.
102. Loskutoff DJ, Linders M, Keijer J, et al: Structure of the human plasminogen activator 133. Mosnier LO, Bouma BN: Regulation of fibrinolysis by thrombin activatable fibrinolysis
inhibitor-1 gene: Non-random distribution of introns. Biochemistry 26:3763–3768, 1987. inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and
103. Mottonen J, Strand A, Symersky J, et al: Structural basis of latency in plasminogen acti- fibrinolysis. Arterioscler Thromb Vasc Biol 26:2445–2453, 2006.
vator inhibitor-1. Nature 355:270–273, 1992. 134. Bajzar L, Manuel R, Nesheim M: Purification and characterization of TAFI, a thrombin
104. Declerck PJ, De Mol M, Alessi MC, et al: Purification and characterization of a plas- activatable fibrinolysis inhibitor. J Biol Chem 270:14477–14484, 1995.
minogen activator inhibitor-1 binding protein from human plasma. Identification as 135. Eaton DL, Malloy BE, Tsai SP, et al: Isolation, molecular cloning, and partial characteri-
multimeric form of S protein (vitronectin). J Biol Chem 263:15454–15461, 1988. zation of a novel carboxypeptidase B from plasma. J Biol Chem 269:21833–21834, 1991.
105. Dupont DM, Madsen JB, Kristensen T, et al: Biochemical properties of plasminogen 136. Wang W, Hendriks DF, Scharpe SS: Carboxypeptidase U, a plasma carboxypeptidase
activator inhibitor-1. Front Biosci 14:1337–1361, 2009. with high affinity for plasminogen. J Biol Chem 269:15937–15944, 1994.
106. Kruithof EK: Regulation of plasminogen activator inhibitor type 1 gene expression by 137. Bajzar L, Nesheim ME, Tracy PB: The profibrinolytic effect of activated protein C in
inflammatory mediators and statins. Thromb Haemost 100:969–975, 2008. clots formed from plasma is TAFI-dependent. Blood 88:2093–2100, 1996.
107. Nagamine Y: Transcriptional regulation of the plasminogen activator inhibitor type 1— 138. Bajzar L, Morser J, Nesheim M: TAFI, or plasma procarboxypeptidase B, couples the
With an emphasis on negative regulation. Thromb Haemost 100:1007–1013, 2008. coagulation and fibrinolytic cascades through the thrombin-thrombomodulin com-
108. Bosma PJ, Van den Berg EA, Kooistra T, et al: Human plasminogen activator inhibitor-1 plex. J Biol Chem 271:16603–16608, 1996.
gene: Promoter and structural nucleotide sequences. J Biol Chem 263:9129–9141, 1988. 139. Minnema MC, Friederich PW, Levi M, et al: Enhancement of rabbit jugular vein throm-
109. Van Zonnefeld AJ, Curriden SA, Loskutoff DJ: Type 1 plasminogen activator inhibitor bolysis by neutralization of factor XI: In vivo evidence for a role of factor XI as an anti-
gene: Functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad fibrinolytic factor. J Clin Invest 101:10–14, 1998.
Sci U S A 85:5525–5529, 1988. 140. Nagashima M, Yin ZF, Zhao L, et al: Thrombin-activatable fibrinolysis inhibitor (TAFI)
110. Westerhausen DR, Hopkins WE, Billadello JJ: Multiple transforming growth factor deficiency is compatible with murine life. J Clin Invest 109(101):110, 2002.
beta-inducible elements regulate expression of the plasminogen activator inhibitor 141. Wang X, Smith PL, Hsu MY, et al: Deficiency in thrombin-activatable fibrinolysis
type-1 gene in HepG2 cells. J Biol Chem 266:1092–1100, 1991. inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
111. Keeton MR, Curriden SA, Van Zonneveld AJ, Loskutoff DJ: Identification of regulatory J Thromb Thrombolysis 23:41–49, 2007.
sequences in the type 1 plasminogen activator inhibitor gene responsive to transform- 142. Mao SS, Holahan MA, Bailey C, et al: Demonstration of enhanced endogenous
ing growth factor. J Biol Chem 266:23048–23052, 1991. fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice. Blood Coagul
Fibrinolysis 16:407–415, 2005.

Kaushansky_chapter 135_p2303-2326.indd 2320 9/18/15 5:14 PM